F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have divulged triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease, frontotemporal dementia, multiple sclerosis, Nasu-Hakola disease, Parkinson’s disease, rheumatoid arthritis and stroke.
It has been previously demonstrated that genetic loss-of-function of triggering receptor expressed on myeloid cells 2 (TREM2) impairs microglia migration, with the TREM2 R47H variant having been linked to increased risk of Alzheimer’s disease (AD) due to impaired microglia clustering and enhanced neuronal damage.
Since microglia play a critical role in resolving amyloid pathology and it has been previously demonstrated that microglia function can be induced by TREM2 activation, TREM2 agonism has been considered a promising novel therapeutic approach to delay or prevent the progression of Alzheimer’s disease.
Muna Therapeutics ApS has disclosed new triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of osteoporosis, rheumatoid arthritis, systemic lupus erythematosus, type 2 diabetes, obesity, metabolic dysfunction-associated steatotic liver disease, neurodegenerative and inflammatory bowel disease, among others.
Two Vigil Neuroscience Inc. patents describe triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of frontotemporal dementia, multiple sclerosis, rheumatoid arthritis, stroke, prion infections, Parkinson’s, Alzheimer’s and Nasu-Hakola diseases.
Vigil Neuroscience Inc. has synthesized triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of frontotemporal dementia, multiple sclerosis, rheumatoid arthritis, stroke, prion infections, Parkinson's, Alzheimer's and Nasu-Hakola diseases.
